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32970
Efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl
peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe
acne: Randomized phase 2 and phase 3 studies of the first triplecombination drug
Linda Stein Gold, MD, Henry Ford Hospital, Detroit, MI; Leon H. Kircik, MD,
Indiana University School of Medicine, Indianapolis, IN; Physicians Skin Care,
PLLC, Louisville, KY; Icahn School of Medicine at Mount Sinai, New York, NY;
Emil A. Tanghetti, MD, Center for Dermatology and Laser Surgery, Sacramento,
CA
A 3-pronged approach to acne treatment—combining an antibiotic, antibacterial,
and retinoid—may provide greater efficacy and tolerability than single/double
treatments while potentially reducing antibiotic resistance and increasing patient
compliance. Clindamycin 1.2%/BPO 3.1%/adapalene 0.15% (IDP-126) gel is the first
triple-combination, fixed-dose topical acne product in development that addresses
the major pathophysiological abnormalities in acne patients. A phase 2 (N ¼ 741)
and two phase 3 (N ¼ 183; N ¼ 180), double-blind, randomized, 12-week studies
enrolled participants aged $9 years with moderate-to-severe acne. Participants were
randomized to receive once-daily IDP-126 or vehicle; the phase 2 study included 3
additional randomization arms containing dyad gels: BPO/adapalene; clindamycin
phosphate/BPO; and clindamycin phosphate/adapalene (data not shown).
Endpoints included participants achieving $2-grade reduction from baseline in
Evaluator’s Global Severity Score and clear/almost clear skin (treatment success) and
least-squares mean percent change from baseline in inflammatory and noninflammatory lesion counts. Treatment-emergent adverse events (TEAEs) were also
assessed. In all 3 studies at week 12, half of participants achieved treatment success
with IDP-126 (phase 2: 52.5%; phase 3: 49.6%, 50.5%) versus less than one-fourth
with vehicle (8.1%; 24.9%, 20.5%; P \.01, all). IDP-126 resulted in [70% reductions
in inflammatory and noninflammatory lesions at week 12, significantly greater than
vehicle (range: inflammatory, 75.7%-80.1% vs 50.4%-59.6%; noninflammatory,
71.0%-73.3% vs 45.8%-49.0%; P \ .001, all). Most TEAEs were of mild-moderate
severity, and \4% of IDP-126-treated participants discontinued study/treatment due
to AEs. The innovative fixed-dose, triple-combination IDP-126 gel was efficacious
and well tolerated in three clinical studies of children, adolescents, and adults with
moderate-to-severe acne.
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Efficacy and safety of baricitinib in adult patients with severe
alopecia areata with or without an atopic background from 2
randomized, placebo-controlled, phase 3 trials
Natasha Atanaskova Mesinkovska, MD, PhD, University of California
Irvine, Irvine, CA; Taisuke Ito, MD, PhD, Hamamatsu University Hospital,
Hamamatsu, Japan; Maryanne Senna, MD, Massachusetts General Hospital,
Boston, MA
Background: Atopy is associated with alopecia areata (AA) and may influence
treatment response. Among 1200 patients enrolled in 2 independent phase 3 trials
of baricitinib for severe AA, 37.8 % had an atopic background, defined by medical
history or ongoing atopic dermatitis, allergic rhinitis, allergic asthma, or allergic
conjunctivitis at baseline. Descriptive treatment efficacy and safety in patients with
or without an atopic background are reported.
Methods: BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) are ongoing
double-blind trials (randomization [3:2:2] to receive once-daily baricitinib 4- mg, 2mg, or placebo). Using pooled data, we evaluated safety and efficacy outcomes
(Severity of Alopecia Tool [SALT] score #20 and Clinician-Reported Outcomes for
Eyebrow Hair Loss and Eyelash Hair Loss scores of 0 or 1 with $2-point
improvement, among those with baseline scores $2) at week 36.
Results: Mean baseline SALT score was 87.2 vs. 84.2 for patients with or without an
atopic background, respectively. At week 36, SALT #20 was achieved by 40.8%,
21.5%, and 2.1% of patients with an atopic background with baricitinib 4- mg, 2- mg,
and placebo, respectively, vs. 30.2%, 18.6%, and 5.4% without an atopic background.
Improvements in eyebrow/eyelash measures occurred in 37.6%/36.5%,
19.1%/15.5%, and 6.0%/6.4% of patients with an atopic background with baricitinib
4- mg, 2- mg, and placebo, respectively, vs. 30.4%/32.3%, 13.7%/9.5%, and 2.2%/2.8%
without an atopic background. The baricitinib safety profile in both subgroups was
similar to that in the overall population.
Conclusion: The safety profile and improvements in hair regrowth in baricitinibtreated patients with severe AA were independent of atopic background.
Commercial Disclosure: 100% sponsored by Eli Lilly and Company.

Commercial Disclosure: Ortho Dermatologics.
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Efficacy and safety of apremilast for the treatment of Japanese
patients with palmoplantar pustulosis: Results from a phase 2,
randomized, placebo-controlled study
Tadashi Terui, MD, PhD, Nihon University School of Medicine; Yukari
Okubo, MD, PhD, Tokyo Medical University, Tokyo, Japan; Satomi Kobayashi,
MD, Seibo International Catholic Hospital, Tokyo, Japan
Background: Palmoplantar pustulosis (PPP) is a pruritic, painful chronic dermatitis,
and approved therapeutic options are limited. This randomized, phase 2 study
(NCT04057937) evaluated apremilast 30 mg BID (APR) efficacy and safety vs
placebo (PBO) for moderate to severe PPP after inadequate response to topical
therapy in Japan.
Methods: The primary endpoint was $50% improvement in PPP Area and Severity
Index (PPPASI-50; chi-square, a ¼ 0.10) at Week 16. Change in Palmoplantar Severity
Index (PPSI) and Subject’s VAS Assessments for pruritus and pain (mixed-effect
model for repeated measures for all), and time to PPPASI-50 (Kaplan-Meier
estimated) were evaluated as secondary endpoints.
Results: In patients receiving APR (n ¼ 46) or PBO (n ¼ 44), mean age (54.7, 54.9
years), PPP duration (7.3, 7.5 years), PPSI (8.3, 8.2), pruritus VAS (50.3, 57.0), and
pain VAS (45.4, 50.3) were similar at baseline. APR demonstrated shorter median
time to PPPASI-50 response than PBO (4.1 [95% CI: 4.0, 6.1] vs 11.9 [8.1, 14.1]
weeks; nominal P\.0001). Greater changes were observed with APR vs PBO in PPSI
(difference: 1.6 [95% CI: 2.4, 0.9]; nominal P \.0001), pruritus VAS (difference: 20.3 [30.6, 9.9]; nominal P ¼ .0002), and pain VAS (difference: 16.1
[25.4, 6.7]; nominal P ¼ .001). At Week 16, PPPASI-50 response rate was
statistically greater with APR vs PBO (78.3% vs 40.9%; P ¼.0003). The most common
adverse events included gastrointestinal events and headache.
Conclusions: Apremilast demonstrated significant and early improvements in PPP
severity, pruritus, and pain. Adverse events were consistent with the known safety
profile.
Commercial Disclosure: This study was sponsored by A mgen Inc. Writing support
was funded by A mgen Inc. and provided by Kristin Carlin, BSPharm, MBA of
Peloton Advantage, LLC, an OPEN Health company, and Dawn Nicewarner, PhD,
employee of and stockholder in A mgen Inc.
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Efficacy and safety of ruxolitinib cream for the treatment of
vitiligo by patient demographics and baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3
studies
David Rosmarin, MD, Tufts Medical Center, Boston, MA; Khaled Ezzedine, MD,
PhD, Henri Mondor University Hospital and Universite Paris-Est Creteil Val de
Marne, Paris, France; Seemal R. Desai, MD, University of Texas Southwestern
Medical Center, Dallas, TX; Innovative Dermatology, Plano, TX
Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream is in development for the
treatment of vitiligo, a chronic autoimmune skin disease. Two phase 3 randomized
studies (TRuE-V1 [NCT04052425]; TRuE-V2 [NCT04057573]) conducted in North
America and Europe enrolled patients aged $12 years with nonsegmental vitiligo
with depigmentation covering #10% total body surface area (BSA). Patients (mean
age, 39.6 years) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream (n ¼ 450)
or vehicle (n ¼ 224) for 24 weeks of double-blind treatment. At Week 24, $75%
improvement from baseline in facial Vitiligo Area Scoring Index (F-VASI75; primary
endpoint) was achieved by significantly more patients who applied ruxolitinib
cream vs vehicle (30.7%/9.9%; P \ .0001). Efficacy by F-VASI75 response was
identified in all demographic and clinical characteristic subgroups. Substantive FVASI75 responses were seen for men ([n ¼ 270], 26.6%/10.8%) and women ([n ¼
322], 33.9%/9.2%) and based on age group (12e17 years [n ¼ 68], 32.1%/0%; 18e64
years [n ¼ 484], 30.2%/11.0%; $65 years [n ¼ 40], 33.3%/7.7%). F-VASI75 responses
were also generally consistent based on Fitzpatrick skin phototype (IeII [n ¼ 193],
27.9%/9.4%; IIIeVI [n ¼ 399], 32.0%/10.2%), facial BSA (\1.5% [n ¼ 484],
29.2%/11.3%; $1.5% [n ¼ 108], 36.8%/3.1%), investigator-assessed disease stability
(stable [n ¼ 438], 29.9%/8.3%; progressive [n ¼ 154], 32.7%/14.9%), and previous
therapy (topical corticosteroids [n ¼ 165], 32.2%/9.1%; topical calcineurin inhibitors [n ¼ 198], 32.4%/6.5%; phototherapy [n ¼ 191], 33.9%/7.8%). Treatmentrelated adverse events occurred in 14.7%/7.6% who applied ruxolitinib cream or
vehicle, respectively, with generally similar rates among demographic subgroups for
patients who applied ruxolitinib cream. In summary, ruxolitinib cream demonstrated similar efficacy and safety results in patients with vitiligo regardless of
demographic or clinical characteristic subgroup.
Commercial Disclosure: This study was funded by Incyte Corporation
(Wilmington, DE).
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